21/11

AmoyDx® Essential NGS panel got approval from Chinese authority

AmoyDx^® Essential NGS panel was approved by Chinese National Medical Products Administration (NMPA) on November 20, 2018, for qualitative detection of gene mutations in patients with Non-Small Cell

11/11

2018 AmoyDx Distributors Annual Meeting successfully held in Shanghai

November 11, 2018 (Shanghai, China) AmoyDx Distributors Annual Meeting 2018 was held in Shanghai on November 8, 2018. 34 delegates from 19 countries gathered together to get the latest market

02/11

Visit AmoyDx at AMP Annual Meeting 2018 in USA

AmoyDx Exhibits in AMP Annual Meeting 2018 (1-3 November, San Antonio, USA) and shows a novel and accurate approach for simultaneous detection of multiple driver gene mutations in NSCLC.

21/09

Visit AmoyDx at the 19th World Conference on Lung Cancer (WCLC) 2018 in Canada

Amoy Diagnostics will be exhibiting at 19th World Conference on Lung Cancer 2018 of IASLC in Toronto, Canada. Welcome to visit us at booth 206.

24/08

Amoy Diagnostics achieved China NMPA Approval of Multi-Genes Mutations Detection Kit

Amoy Diagnostics Co., Ltd. (AmoyDx, SHE:300685) announced that NMPA（National Medical Products Administration）approved its Multi-Genes Mutations Detection Kit on Aug 24, 2018.

04/04

Meet AmoyDx at ELCC 2018 in Switzerland for NSCLC Molecular Testing

Amoy Diagnostics will be exhibiting at the ELCC 2018 in Geneva, Switzerland. Welcome to visit us.  The exhibition details are below.